Haemonetics (NYSE:HAE) Issues Quarterly Earnings Results

Haemonetics (NYSE:HAE) announced its earnings results on Thursday. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.04, FiscalAI reports. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The business had revenue of $338.97 million during the quarter, compared to analyst estimates of $331.90 million. During the same quarter in the previous year, the business earned $1.19 earnings per share. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. Haemonetics updated its FY 2026 guidance to 4.900-5.000 EPS.

Here are the key takeaways from Haemonetics’ conference call:

• Company raised full‑year guidance — reported revenue guidance tightened to a decline of ~1%–3%, organic revenue ex‑CSL raised to ~8%–10%, adjusted EPS now expected at $4.90–$5.00, and free cash flow guidance increased to $200–$220 million.
• Core product momentum — NexSys/TEG and Plasma drove outsized results (TEG adoption and a new heparinase cartridge accelerating conversions; Plasma organic growth ex‑CSL ~20% this quarter and ~22% YTD), with sustained share gains and innovation‑led pricing.
• Interventional Technologies (IVT) remains a drag — IVT revenue fell materially (down 12% Q/Q) due to esophageal cooling weakness, accelerated PFA adoption and OEM headwinds; management expects a turnaround in FY2027 but is investing now, so near‑term performance is challenged.
• Margins and cash generation strengthened — adjusted gross margin ~60%, operating‑margin guidance ~26%–27%, $74M free cash flow in the quarter (YTD $165M), cash balance up to $363M, active buybacks and the $61M Vivisure acquisition funded while keeping leverage manageable.

Haemonetics Stock Down 0.5%

Haemonetics stock traded down $0.32 during trading hours on Thursday, reaching $65.63. The stock had a trading volume of 902,897 shares, compared to its average volume of 853,476. Haemonetics has a 52 week low of $47.31 and a 52 week high of $87.32. The business’s 50 day moving average price is $77.59 and its 200-day moving average price is $65.27. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03. The company has a market cap of $3.07 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 1.35 and a beta of 0.28.

Analysts Set New Price Targets

Several brokerages have commented on HAE. Needham & Company LLC downgraded Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, December 15th. Barrington Research reaffirmed an “outperform” rating and issued a $93.00 price target on shares of Haemonetics in a research note on Monday. Raymond James Financial reissued an “outperform” rating and issued a $90.00 price objective on shares of Haemonetics in a research report on Friday, November 14th. Mizuho upped their target price on shares of Haemonetics from $75.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Finally, Robert W. Baird raised their target price on shares of Haemonetics from $87.00 to $99.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $84.40.

Institutional Trading of Haemonetics

A number of institutional investors have recently made changes to their positions in the business. EverSource Wealth Advisors LLC grew its stake in Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 396 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Haemonetics by 20,925.0% in the third quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock worth $41,000 after acquiring an additional 837 shares in the last quarter. CIBC Private Wealth Group LLC grew its stake in shares of Haemonetics by 69.3% during the third quarter. CIBC Private Wealth Group LLC now owns 1,094 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 448 shares during the last quarter. Quadrant Capital Group LLC acquired a new position in shares of Haemonetics during the third quarter valued at about $76,000. Finally, Strs Ohio purchased a new position in shares of Haemonetics in the 1st quarter valued at approximately $140,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.